Syros Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Syros Pharmaceuticals saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 3,960,000 shares, a drop of 17.2% from the June 30th total of 4,780,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is presently 2.9 days. Approximately 9.4% of the shares of the company are sold short.
View Syros Pharmaceuticals' Short Interest.

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Syros Pharmaceuticals.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.23) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.55) by $0.32. The firm had revenue of $4.83 million for the quarter, compared to analysts' expectations of $3.05 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 92.51% and a negative net margin of 462.00%.
View Syros Pharmaceuticals' earnings history.

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYRS shares have decreased by 7.4% and is now trading at $4.77.
View which stocks have been most impacted by COVID-19.

6 analysts have issued 1 year price targets for Syros Pharmaceuticals' shares. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $17.00 in the next year. This suggests a possible upside of 256.4% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Syros Pharmaceuticals include Kronos Bio (KRON), Arcutis Biotherapeutics (ARQT), Precigen (PGEN), Janux Therapeutics (JANX), Applied Molecular Transport (AMTI), ImmunoGen (IMGN), Dynavax Technologies (DVAX), MannKind (MNKD), Stoke Therapeutics (STOK), Nkarta (NKTX), ChemoCentryx (CCXI), Northwest Biotherapeutics (NWBO), Antibe Therapeutics (ATBPD), Kiniksa Pharmaceuticals (KNSA) and CannTrust (CNTTF).
View all of SYRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYRS stock can currently be purchased for approximately $4.77.

Syros Pharmaceuticals has a market capitalization of $295.06 million and generates $15.09 million in revenue each year. The company earns $-84,040,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

Syros Pharmaceuticals employs 103 workers across the globe.

The official website for Syros Pharmaceuticals is www.syros.com.

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]